2021
DOI: 10.21203/rs.3.rs-242485/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Evaluation of Rivaroxaban- and Dabigatran-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database  (FAERS)

Abstract: Background Rivaroxaban and dabigatran are non-vitamin K antagonist oral anticoagulants that are widely used for treatment and prevention of venous thrombo-embolism and prevention of stroke in patients with atrial fibrillation.Objective To estimate and compare hemorrhagic events reported for rivaroxaban and dabigatran.Setting FDA Adverse Event Reporting System (FAERS) database.Methods The reporting odds ratio (ROR) was used to analyze the reporting of hemorrhagic events.Main outcome measure The overall hemorrha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 21 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?